125
Participants
Start Date
May 7, 2018
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
relacorilant
CORT125134 is supplied as capsules for oral dosing.
Site 14, Vienna
Site 24, New York
Site 31, Bucharest
Site 28, Bucharest
Site 6, Albany
Site 2, Pittsburgh
Site 46, Pittsburgh
Site 25, Milan
Site 45, Lublin
Site 27, Baltimore
Site 17, Madrid
Site 4, Wilmington
Site 38, Málaga
Site 10, Atlanta
Site 50, Miami
Site 48, Padua
Site 34, Jackson
Site 43, Cleveland
Site 1, Indianapolis
Site 8, Ann Arbor
Site 36, Rochester
Site 40, Ancona
Site 9, Chicago
Site 3, St Louis
Site 29, Tel Aviv
Site 5, Metairie
Site 11, Dallas
Site 32, Fort Worth
Site 12, Houston
Site 7, El Paso
Site 21, Napoli
Site 49, Phoenix
Site 55, Reno
Site 39, Torrance
Site 35, Stanford
Site 42, Würzburg
Site 44, Messina
Site 20, Ramat Gan
Site 13, Fall River
Site 51, Nova Scotia
Site 16, Munich
Site 52, Torino
Site 53, Alicante
Site 18, Girona
Site 19, Seville
Site 33, Rotterdam
Site 47, Krakow
Site 37, Bucharest
Lead Sponsor
Corcept Therapeutics
INDUSTRY